Mark Wogulis

Mark Wogulis has been working in the scientific field since 1993. Mark began their career at Elan Pharmaceuticals as a Research Associate I and worked their way up to Scientist. During their time there, they worked on a team which developed in vitro models of neuronal cell death from beta amyloid peptide in order to discover small molecule therapeutics. In 2008, Mark began working at Novozymes as a Staff Scientist. Mark used rational design, site saturation, and biased shuffling methods to improve either thermostability or specific activity in industrial applications for multiple enzymes. Mark is listed as an inventor in 15 patent applications arising from this work. Most recently, Mark has been working as a Principal Scientist at Amyris since 2021.

Mark Wogulis completed their Bachelor of Science in Biology/Biological Sciences, General from Stanford University between 1983 and 1985. Mark then attended Harvard University from 1981 to 1983, studying Biology/Biological Sciences, General. Mark then pursued a Master of Science in Biology, General from Stanford University between 1985 and 1986. Finally, they obtained a Doctor of Philosophy in Biochemistry and Molecular Biology from the University of California, Davis between 2001 and 2006.